General
Preferred name
ENZALUTAMIDE
Synonyms
MDV3100 ()
Xtandi ()
MDV 3100 ()
MDV-3100 ()
F2175 ()
N-Methyl-4-[3-(4-cyano-3-trifluoromethylphenyl)-5,5-dimethyl-4-oxo-2-thioxoimidazolidin-1-yl]-2-fluorobenzamide ()
HC-1119 ()
DEUTENZALUTAMIDE ()
Enzalutamide (MDV3100) ()
HC 1119 ()
Hc1119 ()
Enzalutamide d3 ()
P&D ID
PD004101
CAS
915087-33-1
1443331-82-5
Tags
drug candidate
natural product
drug
available
Approved by
PMDA
FDA
First approval
2012
Drug Status
investigational
approved
Drug indication
Prostate cancer
Max Phase
Phase 4
Phase 3
Probe control
Probe control not defined
Orthogonal probes
0
No orthogonal probes found
Similar probes
0
No structurally similar probes found
Structure
P&D probe-likeness score
Structure formats
[[ format ]]
[[ compound[format === 'MOL' ? 'molblock' : format.toLowerCase()] ]]
Description
(extracted from source data)
DESCRIPTION
Enzalutamide is an androgen receptor antagonist.
(GtoPdb)
ABSORPTION
The pharmacokinetic profile of enzalutamide and N-desmethyl enzalutamide (its major active metabolite) is described by a linear two-compartment model with first-order absorption. Enzalutamide also accumulates. Food does not affect its absorption. ; Tmax, prostate cancer patients = 1 hour (range of 0.5-3 hours);; Cmax, steady state, enzalutamide = 16.6 μg/mL;; Cmax, steady state, N-desmethyl enzalutamide = 12.7 μg/mL;; Time to steady state, daily dosing = 28 days;
DESCRIPTION
Enzalutamide is an androgen receptor antagonist
[[ p.pathway_name ]]
[[ compound.targets[tid].gene_name ]]
Cell lines
9
Organisms
0
Compound Sets
27
AdooQ Bioactive Compound Library
Axon Medchem Screening Library
Cayman Chemical Bioactives
ChEMBL Approved Drugs
ChEMBL Drugs
Concise Guide to Pharmacology 2017/18
Concise Guide to Pharmacology 2019/20
Concise Guide to Pharmacology 2021/22
Concise Guide to Pharmacology 2023/24
Drug Repurposing Hub
DrugBank
DrugBank Approved Drugs
DrugCentral
DrugCentral Approved Drugs
DrugMAP Approved Drugs
Guide to Pharmacology
LINCS compound set
Mcule NIBR MoA Box Subset
MedChem Express Bioactive Compound Library
Natural product-based probes and drugs
NCATS Inxight Approved Drugs
NIH Approved Oncology Drugs
Novartis Chemogenetic Library (NIBR MoA Box)
ReFrame library
Selleckchem Bioactive Compound Library
TargetMol Bioactive Compound Library
[[ a.name ]]
[[ ligand_id ]]
free of charge
External IDs
39
Molecular Weight
464.09
Hydrogen Bond Acceptors
4
Hydrogen Bond Donors
1
Rotatable Bonds
3
Ring Count
3
Aromatic Ring Count
2
cLogP
3.99
TPSA
76.44
Fraction CSP3
0.24
Chiral centers
0.0
Largest ring
6.0
QED
0.55
Structural alerts
0
No structural alerts detected
Related compounds
Custom attributes
(extracted from source data)
Pathway
Endocrinology/Hormones
Autophagy
Vitamin D Related/Nuclear Receptor
Target
Androgen Receptor
AR
AR antagonist
Androgen Receptor,Autophagy
MOA
androgen receptor
Androgen Receptor Antagonists
Androgen Receptor antagonist
Member status
member
Indication
prostate cancer
Therapeutic Indication
Anticancer
Source data
